Asked by: Jeremy Lefroy (Conservative - Stafford)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Innovation and Skills, if he will publish in full the responses to Question 3 of the Government's consultation, Devolving Sunday trading rules, published on 5 August 2015, before Report Stage of the Enterprise Bill [Lords].
Answered by Anna Soubry
The Government published its response to the consultation on 9 February, in which it sets out its proposals to devolve Sunday trading rules to a local level. The Government has no plans to publish in full the responses at this time.
Asked by: Jeremy Lefroy (Conservative - Stafford)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Innovation and Skills, how many small business groups and coalitions responded to the Government's consultation, Devolving Sunday trading rules, published on 5 August 2015; and what (a) number and (b) proportion of those respondents answered (i) yes, (ii) no and (iii) otherwise to Question 1 in that consultation.
Answered by Anna Soubry
The Department does not hold full data from this consultation broken down by specific question as a large portion of respondents chose to respond in their own words rather than addressing the consultation questions directly, and/or did not indicate the type of organisation they represented.
Asked by: Jeremy Lefroy (Conservative - Stafford)
Question to the Department for Business, Energy and Industrial Strategy:
To ask the Secretary of State for Business, Innovation and Skills, what information his Department holds on how many new antibiotics are in development by UK companies.
Answered by George Freeman
The Department does not hold information on how many new antibiotics are in development by UK companies.
The independent review on antimicrobial resistance led by Lord O’Neill publication Securing New Drugs for Future Generations – the Pipeline of antibiotics, provides a high-level assessment of the development pipeline for new antibiotics: